Dr. Jonathan Friedberg discusses an experimental targeted oral agent, fostamatinib, that's being used to treat diffuse large B-cell lymphoma and chronic lymphocytic leukemia. Jane MacNeil of Elsevier Global Medical News (EGMN) reports from the annual meeting of the American Society of Hematology.